> ## Content Index > Fetch the complete content index at: https://dotsexual.com/llms.txt > Use this file to discover other available public pages before exploring further. # Finasteride and Sexual Side Effects: Clinical Trial Rates, Regulator Labels and Persistence Claims - URL: https://dotsexual.com/finasteride-sexual-side-effects-regulator-warnings-evidence/ - Published: 2026-10-22T09:24:52.000Z - Updated: 2026-10-23T09:12:03.000Z - Description: In Phase III hair-loss trials, sexual side effects occurred in 3.8% of men on finasteride 1 mg vs 2.1% on placebo—yet FDA, MHRA, EMA and Health Canada labels warn of post-discontinuation persistence and mood risks. - Author: Dot Research Desk - Tags: Research, #zone-a, #asked-online, #chart, #living-page, #review-in-28d **In pooled Phase III randomized clinical trials of oral finasteride 1 mg for male pattern hair loss, sexual side effects were uncommon—reported by 3.8% of men on finasteride versus 2.1% on placebo—and resolved in trial participants who stopped the drug or continued treatment. However,** [**post-marketing safety reviews by the UK MHRA (2024–2026)**](https://assets.publishing.service.gov.uk/media/6825bc05a4c1a40fde4e63e7/Finasteride%5FPAR%5FAccessible%5F1206.pdf?ref=dotsexual.com)**,** [**the European Medicines Agency (EMA)**](https://www.pfsfoundation.org/news/european-medicines-agency-confirms-finasteride-can-cause-suicidal-thoughts/?ref=dotsexual.com)**, Health Canada and the** [**U.S. FDA**](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com) **have required warnings on all finasteride labels stating that decreased libido, erectile dysfunction and ejaculation disorders have been reported to persist after stopping treatment in some men, alongside warnings for depressed mood and suicidal ideation.** *Scope and method:* This guide compares clinical trial incidence rates (1 mg vs 5 mg), nocebo study findings, post-marketing pharmacovigilance data, and official regulator actions across the US, UK, EU and Canada checked on 22 October 2026\. It is educational information and does not replace advice from your prescribing clinician; see our [Medical Disclaimer](https://dotsexual.com/medical-disclaimer/). > **Asked online (paraphrased):** “Hair-loss clinics say finasteride side effects only happen to 1%–2% of men and always vanish if you stop, while forums say it permanently ruins erections and mood. Why is there such a huge gap between the clinical trial numbers and the regulator warnings on the box?” ## Important UK MHRA / EMA safety rule: 1 mg (hair loss) vs 5 mg (prostate) In April 2024 and May 2026, the [UK Medicines and Healthcare products Regulatory Agency (MHRA)](https://assets.publishing.service.gov.uk/media/6630a6d03579e7a8f398a9a6/April%5FDSU.pdf?ref=dotsexual.com) and [European regulators](https://pharmaceutical-journal.com/article/news/psychiatric-and-sexual-dysfunction-warnings-strengthened-for-finasteride-and-dutasteride?ref=dotsexual.com) issued updated safety guidance and mandatory patient alert cards with an important clinical distinction: - **If you take finasteride 1 mg for male pattern hair loss (androgenetic alopecia)** and develop **depression, low mood or suicidal thoughts**, the MHRA advises stopping treatment **immediately** and contacting a healthcare professional. - **If you take finasteride 5 mg (or dutasteride) for benign prostatic hyperplasia (enlarged prostate)** and develop psychiatric or sexual symptoms, consult your prescribing doctor urgently for medical advice before stopping, so urinary retention risk is managed safely. - If you or someone you know is experiencing suicidal thoughts, seek emergency medical support immediately (see [Talk to a Real Clinician](https://dotsexual.com/talk-to-a-clinician/)). ## What finasteride changes in androgen and neurosteroid biology Finasteride is a competitive inhibitor of the **type II (and type III) 5-alpha-reductase** enzyme, which converts testosterone into the much more potent androgen **dihydrotestosterone (DHT)**. At the 1 mg/day hair-loss dose, finasteride lowers serum and scalp DHT by roughly **65% to 70%** while slightly raising circulating testosterone by \~10%–15% (dutasteride inhibits both type I and type II isoenzymes, lowering serum DHT by >90%). Because testosterone—not DHT—is the primary androgen driving adult erectile function and libido in most men, the vast majority of men taking finasteride maintain normal sexual function. However, 5-alpha-reductase is also expressed in the prostate, seminal vesicles, corpus cavernosum smooth muscle, and the central nervous system (where it converts progesterone and deoxycorticosterone into neurosteroids such as **allopregnanolone** that modulate GABA-A mood and arousal pathways). Reduction in prostatic/seminal fluid production explains why a slightly smaller, more watery ejaculate volume is a known pharmacological effect on the drug (see [Semen Sample Rules](https://dotsexual.com/semen-sample-abstinence-rules/)). ## Clinical trial incidence: finasteride 1 mg vs 5 mg vs placebo The table below shows the exact adverse-event rates recorded in the pivotal randomized, double-blind, placebo-controlled trials reported in [FDA prescribing information](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com) and the [MHRA Public Assessment Report](https://assets.publishing.service.gov.uk/media/6825bc05a4c1a40fde4e63e7/Finasteride%5FPAR%5FAccessible%5F1206.pdf?ref=dotsexual.com). | Sexual adverse event (Year 1 controlled trials) | Finasteride 1 mg (Hair loss, n = 945) | Placebo (Hair loss, n = 934) | Finasteride 5 mg (BPH / PLESS trial, n = 1,524) | Placebo (BPH / PLESS trial, n = 1,516) | | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---------------------------- | ------------------------------------------------------------------------ | ------------------------------------------------- | | **Decreased libido (sex drive)** | **1.8%** | 1.3% | **6.4%** | 3.4% | | **Erectile dysfunction** | **1.3%** | 0.7% | **8.1%** | 3.7% | | **Ejaculation disorder (including reduced ejaculate volume)** | **1.2%** (0.8% decreased volume) | 0.7% (0.4% decreased volume) | **3.7%** (decreased volume) / **0.8%** (other) | 0.8% / 0.1% | | **One or more sexual adverse events (combined)** | **3.8%** (36 / 945 men) | **2.1%** (20 / 934 men) | Higher overall in older BPH cohorts with baseline vascular comorbidities | Higher baseline rate than young hair-loss cohorts | | **Pooled meta-analysis relative risk (Lee et al., cited by [MHRA 2024](https://assets.publishing.service.gov.uk/media/6825bc05a4c1a40fde4e63e7/Finasteride%5FPAR%5FAccessible%5F1206.pdf?ref=dotsexual.com))** | Across male pattern hair loss RCTs, finasteride 1 mg carried a relative risk of **1.60 (95% CI 1.2 to 2.3)** vs placebo for any sexual adverse event (an absolute risk increase of \~1.5 to 2 percentage points above placebo) | | | | ## Why clinical trials and post-marketing reports look so different As [reviews in *Fertility and Sterility*](https://www.fertstert.org/article/S0015-0282%2819%2932599-3/fulltext?ref=dotsexual.com) and the [MHRA Public Assessment Report](https://assets.publishing.service.gov.uk/media/6825bc05a4c1a40fde4e63e7/Finasteride%5FPAR%5FAccessible%5F1206.pdf?ref=dotsexual.com) explain, three methodological factors account for the tension between clinical trials and online reports: 1. **A strong, experimentally proven nocebo effect in pre-warned patients:** In a well-known blinded clinical study (Mondaini et al.), men prescribed finasteride who were explicitly counselled beforehand that the drug might cause erectile dysfunction, low libido and ejaculation problems reported sexual side effects at **43.6%**—compared with **15.3%** among men given the exact same drug without the specific sexual warning. Expecting erection failure triggers performance anxiety and sympathetic vasoconstriction during sex. 2. **Passive trial reporting vs long-term real-world exposure:** Many early hair-loss trials relied on passive self-reporting at clinic visits rather than validated sexual-function questionnaires (IIEF), and followed limited sample sizes (\~945 men on 1 mg), which is statistically too small to detect rare events occurring in 1 in 1,000 or 1 in 10,000 users after discontinuation. 3. **Spontaneous pharmacovigilance signals (FAERS, Yellow Card, EudraVigilance):** Between 1998 and 2011, the [U.S. FDA reviewed 421 post-marketing reports](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com) of sexual dysfunction with finasteride 1 mg, including 59 cases where symptoms persisted for ≥3 months after stopping. Up to April 2024, the [UK MHRA logged 426 Yellow Card reports](https://assets.publishing.service.gov.uk/media/6630a6d03579e7a8f398a9a6/April%5FDSU.pdf?ref=dotsexual.com) of persistent sexual dysfunction after finasteride discontinuation. Because voluntary reporting databases lack a denominator and a control group, regulators note they **cannot calculate a true incidence rate or prove causation in every individual report**—which is why labels state that persistence has been reported with frequency “not known.” ## Global regulator label warnings for finasteride (US, UK, EU, Canada) | Regulator | Key regulatory milestones | Current official label warning on sexual function, fertility & mood | | -------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | **U.S. FDA (United States)** | **2011 / April 2012** sexual label revision; **2022/2023** psychiatric update ([FDA Safety Communication](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com)) | Post-marketing Experience section includes libido disorders, erectile dysfunction, ejaculation disorders and orgasm disorders *“that continued after discontinuation of the drug,”* male infertility and/or poor seminal quality (that normalized or improved after stopping), plus depression and suicidal ideation | | **UK MHRA (United Kingdom)** | **April 2024** Drug Safety Update & **May 2024 / May 2026** PAR updates ([MHRA DSU](https://assets.publishing.service.gov.uk/media/6630a6d03579e7a8f398a9a6/April%5FDSU.pdf?ref=dotsexual.com)) | Mandatory **Patient Alert Card** in every pack warning that finasteride can cause depression/suicidal thoughts and sexual dysfunction (decreased sex drive, erectile dysfunction, ejaculation problems) which *“in some cases continued after treatment was stopped”* | | **European Medicines Agency (EMA — EU/EEA)** | **2018 PRAC** update & **2025/2026** PRAC safety review ([Pharmaceutical Journal](https://pharmaceutical-journal.com/article/news/psychiatric-and-sexual-dysfunction-warnings-strengthened-for-finasteride-and-dutasteride?ref=dotsexual.com)) | EU SmPC warns that sexual dysfunction may persist after discontinuation and confirms suicidal ideation as an adverse reaction (with patient reminder cards introduced for 1 mg packs) | | **Health Canada (Canada)** | **2012** persistent sexual AE update; **2015–2023** suicidality reviews | Canadian product monographs warn of post-discontinuation persistence of sexual adverse events and advise screening/monitoring for mood changes and suicidal ideation | ## What if you are trying to conceive or banking a semen sample? - **Semen volume and sperm counts:** While randomized trials in healthy men showed no effect on spermatogenesis in most users, [FDA post-marketing reviews](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com) documented cases of reduced sperm count or motility (particularly in men with pre-existing subfertility risk factors) that improved or normalized after stopping finasteride. If you are actively trying to conceive and have abnormal semen parameters, discuss pausing finasteride with your fertility specialist (remembering that one full human spermatogenesis cycle takes \~74 days; see [Semen Sample Abstinence Rules](https://dotsexual.com/semen-sample-abstinence-rules/)). - **Partner pregnancy handling rule (crushed or broken tablets):** Because 5-alpha-reductase inhibitors can impair external genital development of a male fetus, pregnant partners (or partners who may become pregnant) must never handle crushed or broken finasteride tablets. Whole film-coated tablets and trace levels of finasteride in semen (\~nanogram quantities) were evaluated by FDA and MHRA as not posing a teratogenic risk via semen, though many couples use condoms or pause 1 mg cosmetic treatment during conception attempts for peace of mind. ## Questions to discuss with your prescriber before starting—or if symptoms appear 1. *“Before I start finasteride 1 mg, can we note my baseline sexual function and mood, and discuss whether topical minoxidil or a lower/topical exposure strategy suits my goals?”* 2. *“If I notice a drop in libido, erection firmness or ejaculate volume while taking finasteride, what is our plan for pausing or stopping and re-evaluating after washout?”* 3. *“If my partner and I plan to try for pregnancy in the next 6 to 12 months, should I pause finasteride 1 mg or do a baseline semen analysis?”* (See also [Antidepressants and Sexual Side Effects](https://dotsexual.com/antidepressants-ssri-snri-sexual-side-effects-pssd-evidence/) and [Talk to a Real Clinician](https://dotsexual.com/talk-to-a-clinician/).) ## Sources and evidence notes 1. UK Medicines and Healthcare products Regulatory Agency (MHRA) — [Safety Review of Finasteride: Public Assessment Report (May 2024)](https://assets.publishing.service.gov.uk/media/6825bc05a4c1a40fde4e63e7/Finasteride%5FPAR%5FAccessible%5F1206.pdf?ref=dotsexual.com) (checked 22 October 2026). 2. UK Medicines and Healthcare products Regulatory Agency (MHRA) — [Drug Safety Update: Finasteride — Reminder of the Risk of Psychiatric and Sexual Side Effects (April 2024)](https://assets.publishing.service.gov.uk/media/6630a6d03579e7a8f398a9a6/April%5FDSU.pdf?ref=dotsexual.com) (checked 22 October 2026). 3. Medscape / U.S. FDA — [FDA Announces Safety Label Changes to Finasteride (Propecia 1 mg & Proscar 5 mg)](https://www.medscape.com/viewarticle/761948?ref=dotsexual.com) (checked 22 October 2026). 4. *Fertility and Sterility* (Elsevier) — [Post-Finasteride Syndrome: A Surmountable Challenge for Clinicians](https://www.fertstert.org/article/S0015-0282%2819%2932599-3/fulltext?ref=dotsexual.com) (checked 22 October 2026). 5. *The Pharmaceutical Journal* (UK, May 2026) — [Psychiatric and Sexual Dysfunction Warnings Strengthened for Finasteride and Dutasteride](https://pharmaceutical-journal.com/article/news/psychiatric-and-sexual-dysfunction-warnings-strengthened-for-finasteride-and-dutasteride?ref=dotsexual.com) (checked 22 October 2026). *Method & corrections:* See [How We Research](https://dotsexual.com/how-we-research/) and [Corrections](https://dotsexual.com/corrections/).